BioSpace News Archive

The latest market analysis report published by Reports and Data, titled ‘Global Lumbar Disc Disease Treatment Market – Forecast to 2030,’ thoroughly examines the Lumbar Disc Disease Treatment industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Osteosarcoma Market – Forecast to 2030,’ thoroughly examines the Osteosarcoma industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Ovarian Cancer Treatment Market – Forecast to 2030,’ thoroughly examines the Ovarian Cancer Treatment industry to provide essential data & information for the targeted readers.

The Alzheimer’s Drug Discovery Foundation (ADDF) is encouraged to see the positive data reported today by Eisai and Biogen for their amyloid-clearing monoclonal antibody lecanemab.

NuGen Medical Devices Inc. announces that, further to its press release on September 15, 2022, the TSX Venture Exchange has approved the Company’s application to extend the expiry date and reduce the exercise price of an aggregate of 7,500,000 outstanding common share purchase warrants of the Company.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that nearly 2,000 people with amyotrophic lateral sclerosis (ALS) have received RADICAVA ORS® (edaravone).

From an early age, children with life-threatening food allergies are taught to proceed with caution: check labels, ask about ingredients, don’t eat something at a friend’s house if you don’t know what is in it.

Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that the results of its positive Phase 2 istaroxime study in early cardiogenic shock were published in the European Journal of Heart Failure (https://doi.org/10.1002/ejhf.2629).

Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, today announced the appointment of David Sans, FAARM, Ph.D, MBA, in New York as Head of Corporate Development.

MorphoSys U.S. Inc. today announced data from the ongoing L-MIND study showing that Monjuvi® (tafasitamab-cxix) plus lenalidomide followed by Monjuvi monotherapy provided long-term efficacy in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated for at least 2 years, including six patients on treatment for 5 years or more.